GLP1R agonists, such as liraglutide and semaglutide, originally developed for the treatment of T2DM, have demonstrated significant effectiveness in managing obesity based on their incretin effects and have been approved by FDA for the treatment of obesity [92]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.